1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar
4;144(5):646-74.
2 Torre LA, Siegel RL, Ward EM, et al. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer 2Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27.
3 Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-1953.
4 Barbot AC, Mussault P, Ingrand P, et al. Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. J Clin Oncol. 2008 May 20;26(15):2538-43.
5 Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952.
Schwertfeger KL, Cowman MK, Telmer PG, et al. Hyaluronan, Inflammation, and Breast Cancer
Progression. Front Immunol. 2015 Jun 8;6:236.
Isakova JT, Vinnikov D, Kipen VN, et al. Gene-to-gene interactions and the association of
TP53, XRCC1, TNFα, HMMR, MDM2 and PALB2 with breast cancer in Kyrgyz females. Breast Cancer. 2020 Sep;27(5):938-946.
Lin A, Feng J, Chen X, et al. High levels of truncated RHAMM cooperate with dysfunctional
p53 to accelerate the progression of pancreatic cancer. Cancer Lett. 2021 Aug 28;514:79-89.
Stevens LE, Cheung WKC, Adua SJ, et al. Extracellular Matrix Receptor Expression in
Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases. Cancer Res. 2017 Apr 15;77(8):1905-1917.
Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications
for cancer immunotherapy. Genome Biol. 2016 Aug 22;17(1):174.
Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape.
Genome Biol. 2017 Nov 15;18(1):220. doi: 10.1186/s13059-017-1349-1.
Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-
infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016 Oct 20;17(1):218.
Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue
expression profiles. Nat Methods. 2015 May;12(5):453-7.
Racle J, de Jonge K, Baumgaertner P, et al. Simultaneous enumeration of cancer and
immune cell types from bulk tumor gene expression data. Elife. 2017 Nov 13;6:e26476.
Finotello F, Mayer C, Plattner C, et al. Molecular and pharmacological modulators of the
tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019 May 24;11(1):34.
Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer [published
correction appears in Immunity. 2019 Aug 20;51(2):411-412]. Immunity. 2018;48(4):812-830.e14.
Bonneville R, Krook MA, Kautto EA, et al. Landscape of Microsatellite Instability Across
39 Cancer Types. JCO Precis Oncol. 2017;2017:PO.17.00073.
18 Hardwick C, Hoare K, Owens R, et al. Molecular cloning of a novel hyaluronan receptor that
mediates tumor cell motility. J Cell Biol. 1992 Jun;117(6):1343-50.
19 Li H, Kroll T, Moll J, et al. Spindle Misorientation of Cerebral and Cerebellar Progenitors Is
a Mechanistic Cause of Megalencephaly. Stem Cell Reports. 2017 Oct 10;9(4):1071-1080.
20 Liu W, Ma J, Cheng Y, et al. HMMR antisense RNA 1, a novel long noncoding RNA, regulates
the progression of basal-like breast cancer cells. Breast Cancer (Dove Med Press). 2016 Nov 24;8:223-229.
21 Maxwell CA, Benítez J, Gómez-Baldó L, et al. Interplay between BRCA1 and RHAMM
regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol. 2011 Nov;9(11):e1001199.
22 Lu D, Bai X, Zou Q, et al. Identification of the association between HMMR expression and
progression of hepatocellular carcinoma via construction of a co-expression network. Oncol Lett. 2020 Sep;20(3):2645-2654.
23 Zhou Z, Li Y, Hao H, et al. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular
Carcinoma by Bioinformatics Analysis. Cell Transplant. 2019 Dec;28(1_suppl):76S-86S.
24 Ghandi M, Huang FW, Jané-Valbuena J,et al. Next-generation characterization of the
Cancer Cell Line Encyclopedia. Nature. 2019 May;569(7757):503-508.
25 Rizzardi AE, Rosener NK, Koopmeiners JS, et al. Evaluation of protein biomarkers of prostate
cancer aggressiveness. BMC Cancer. 2014 Apr 5;14:244.
26 Yeh MH, Tzeng YJ, Fu TY,et al. Extracellular Matrix-receptor Interaction Signaling Genes
Associated with Inferior Breast Cancer Survival. Anticancer Res. 2018 Aug;38(8):4593-4605.
27 Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With
a report of ten original cases. 1893. Clin Orthop Relat Res. 1991 Jan;(262):3-11.
28 Amarnath S, Mangus CW, Wang JC, et al. The PDL1-PD1 axis converts human TH1 cells into
regulatory T cells. Sci Transl Med. 2011 Nov 30;3(111):111ra120.
29 Fourcade J, Sun Z, Pagliano O, et al. CD8(+) T cells specific for tumor antigens can be
rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012 Feb 15;72(4):887-96.
30 Le Mercier I, Chen W, Lines JL, et al. VISTA Regulates the Development of Protective
Antitumor Immunity. Cancer Res. 2014 Apr 1;74(7):1933-44.
31 Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes
reveals the landscape of tumor mutational burden. Genome Med. 2017 Apr 19;9(1):34.
32 Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid
tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409-413.
33 Shihabudeen Haider Ali MS, Cheng X, Moran M, et al. LncRNA Meg3 protects endothelial
function by regulating the DNA damage response. Nucleic Acids Res. 2019 Feb 20;47(3):1505-1522.
34 Dominguez D, Tsai YH, Gomez N, et al. A high-resolution transcriptome map of cell cycle
reveals novel connections between periodic genes and cancer. Cell Res. 2016 Aug;26(8):946-62.
35 Bazzoun D, Adissu HA, Wang L, et al. Connexin 43 maintains tissue polarity and regulates
mitotic spindle orientation in the breast epithelium. J Cell Sci. 2019 May 16;132(10):jcs223313.